A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer

Official Title

A Phase 1/2 Study of BMS-986183 in Subjects With Advanced Hepatocellular Carcinoma

Summary:

The purpose of this study is to evaluate the safety and tolerability of BMS-986183 in patients with liver cancer.

Trial Description

Primary Outcome:

  • Incidence of Adverse Events at Its Worst Grade
  • Incidence of Serious Adverse Events at Its Worst Grade
  • Incidence of Adverse Events Leading to Discontinuation
  • Incidence of Adverse Events Leading to Death
  • Incidence of Laboratory Test Toxicity Grade Shifting From Baseline
Secondary Outcome:
  • Best Overall Response (BOR)
  • Overall Response Rate (ORR)
  • Duration of Response (DoR)
  • Progression Free Survival (PFS)
  • PFS Rate at Week 't'
  • Maximum Observed Concentration (Cmax)
  • Time of Maximum Observed Concentration (Tmax)
  • Area Under the Concentration-time Curve From Time 0 to T of the Last Quantifiable Concentration [AUC(0-T)]
  • Area Under the Concentration-time Curve in 1 Dosing Interval [AUC(TAU)]
  • Concentration at the End of a Dosing Interval (Ctau)
  • Trough Observed Concentration, Including Predose Concentrations and Ctau (Ctrough)
  • Total Body Clearance (CLT)
  • Apparent Volume of Distribution at Steady-state (Vss)
  • Volume of Distribution of Terminal Phase (Vz)
  • Accumulation Index; Ratio of Cmax at Steady-state to Cmax After the First Dose (AI_Cmax)
  • Accumulation Index; Ratio of Ctau at Steady-state to Ctau After the First Dose (AI_Ctau)
  • Accumulation Index; Ratio of AUC(TAU) at Steady-state to AUC(TAU) After the First Dose [AI_AUC(TAU)]
  • Average Concentration Over a Dosing Interval Calculated by Dividing AUC(TAU) at Steady State by Tau (Css,Ave)
  • Terminal Half-life (T-HALF)
  • Changes in QTcF (ΔQTcF) From Baseline
  • Incidence of Positive Anti-drug Antibody (ADA)

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society